ralimetinib

MAPK activated protein kinase 2 ; Homo sapiens







2 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 24356814 Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity. 2014 Feb 2
2 23335506 LY2228820 dimesylate, a selective inhibitor of p38 mitogen-activated protein kinase, reduces angiogenic endothelial cord formation in vitro and in vivo. 2013 Mar 1 1